| pubmed-article:10411340 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10411340 | lifeskim:mentions | umls-concept:C0007959 | lld:lifeskim |
| pubmed-article:10411340 | lifeskim:mentions | umls-concept:C0025936 | lld:lifeskim |
| pubmed-article:10411340 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:10411340 | lifeskim:mentions | umls-concept:C0241764 | lld:lifeskim |
| pubmed-article:10411340 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:10411340 | lifeskim:mentions | umls-concept:C1517945 | lld:lifeskim |
| pubmed-article:10411340 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:10411340 | pubmed:dateCreated | 1999-7-27 | lld:pubmed |
| pubmed-article:10411340 | pubmed:abstractText | X-linked Charcot-Marie-Tooth disease (CMTX) is an inherited demyelinating neuropathy caused by mutations in the gene encoding the gap junction protein connexin32 (Cx32). Despite the identification of over 160 different mutations in the Cx32 coding sequence, it is not known whether the mutations cause the disease manifestations through a loss of Cx32 function or through toxic effects on peripheral nerve. We created transgenic mice with a frameshift mutation at codon 175 (175fs), identified in a large CMTX pedigree. Light microscopic examination of the peripheral nerves from adult transgenic animals showed no pathological features. Western blotting did not show transgenic Cx32 protein in any of the 26 lines, although expression of transgenic messenger RNA was detected by reverse-transcriptase polymerase chain reaction and by ribonuclease protection assay. Our findings indicate that the 175fs mutation results in a loss of Cx32 function, without additional toxic effects. | lld:pubmed |
| pubmed-article:10411340 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411340 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10411340 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411340 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10411340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411340 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10411340 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10411340 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:10411340 | pubmed:issn | 0022-3069 | lld:pubmed |
| pubmed-article:10411340 | pubmed:author | pubmed-author:MessinaOO | lld:pubmed |
| pubmed-article:10411340 | pubmed:author | pubmed-author:FischbeckK... | lld:pubmed |
| pubmed-article:10411340 | pubmed:author | pubmed-author:SchererS SSS | lld:pubmed |
| pubmed-article:10411340 | pubmed:author | pubmed-author:AbelAA | lld:pubmed |
| pubmed-article:10411340 | pubmed:author | pubmed-author:BoneL JLJ | lld:pubmed |
| pubmed-article:10411340 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10411340 | pubmed:volume | 58 | lld:pubmed |
| pubmed-article:10411340 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10411340 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10411340 | pubmed:pagination | 702-10 | lld:pubmed |
| pubmed-article:10411340 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:meshHeading | pubmed-meshheading:10411340... | lld:pubmed |
| pubmed-article:10411340 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10411340 | pubmed:articleTitle | Studies in transgenic mice indicate a loss of connexin32 function in X-linked Charcot-Marie-Tooth disease. | lld:pubmed |
| pubmed-article:10411340 | pubmed:affiliation | Neurogenetics Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1250, USA. | lld:pubmed |
| pubmed-article:10411340 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10411340 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10411340 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:14618 | entrezgene:pubmed | pubmed-article:10411340 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10411340 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10411340 | lld:pubmed |
